119th Congress · introduced in the House · Feb 25, 2026
Recognizing the significance of Charcot-Marie-Tooth disease and the need for robust funding of the National Institute of Neurological Disorders and Stroke at the National Institutes of Health.
Official title from Congress.gov
Latest action (Feb 25, 2026): Referred to the House Committee on Energy and Commerce.
View on Congress.govPolicy area: Health
Congressional Research Service summary, version: Introduced in House (Feb 25, 2026)
This resolution recognizes that Charcot-Marie-Tooth (CMT) disease is significant and expresses the sense that CMT should receive robust funding for research. CMT disease is a neurological disorder that causes damage to the peripheral nerves.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Referred to the House Committee on Energy and Commerce.
Submitted in House
Submitted in House
Actions from Congress.gov, newest first.
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 24, 2026.
No matching lobbying reports found within coverage